Insider Selling: Medpace (NASDAQ:MEDP) Director Sells $4,414,590.45 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Fred Davenport, Jr. sold 7,283 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the transaction, the director directly owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Medpace Stock Up 1.3%

MEDP traded up $8.11 during midday trading on Friday, hitting $620.75. 225,439 shares of the company were exchanged, compared to its average volume of 347,887. The firm’s 50 day moving average price is $547.09 and its 200-day moving average price is $491.80. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The firm has a market capitalization of $17.33 billion, a P/E ratio of 36.39, a P/E/G ratio of 2.71 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the firm posted $3.10 earnings per share. The business’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on MEDP shares. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and increased their target price for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. BMO Capital Markets boosted their price target on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. TD Cowen lifted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average target price of $584.18.

Institutional Investors Weigh In On Medpace

Large investors have recently added to or reduced their stakes in the business. BOKF NA boosted its stake in shares of Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares during the period. Valeo Financial Advisors LLC increased its stake in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after buying an additional 21 shares during the period. UMB Bank n.a. lifted its holdings in Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after buying an additional 24 shares in the last quarter. Schulhoff & Co. Inc. lifted its holdings in Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after buying an additional 25 shares in the last quarter. Finally, Balefire LLC boosted its position in Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after buying an additional 26 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.